
Telix Pharmaceuticals Appoints Dr Colin Hayward as Chief Medical Officer
News,
Telix Pharmaceuticals announces that Dr Colin Hayward has joined Telix’s executive leadership team in the role of Chief Medical Officer…
Read moreNews & Views
News,
Telix Pharmaceuticals announces that Dr Colin Hayward has joined Telix’s executive leadership team in the role of Chief Medical Officer…
Read moreTelix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29…
Read moreTelix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings…
Read moreTelix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for…
Read moreTelix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of…
Read moreARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement…
Read moreTelix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing…
Read moreTelix has submitted a marketing authorisation application (MAA) in Europe for…
Read moreTelix Pharmaceuticals Limited provides a shareholder walkthrough of it’s recently acquired Seneffe manufacturing…
Read moreTelix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry…
Read more